Kymera Stock 130%: $135 Million Buy Boosts Immunology Bet
A major stake in Kymera Therapeutics highlights growing investor optimism in targeted protein degradation. This artic...
This guide covers the fees that can affect the Dividend Aristocrats ETF, from management to trading costs, with tips for evaluating their impact.
11,478 articlesA major stake in Kymera Therapeutics highlights growing investor optimism in targeted protein degradation. This artic...
XRP sits at a critical price crossroads across its USD and BTC pairings, signaling a make-or-break moment for the tok...
Goldman Sachs-backed GPIQ is carving out a niche as a high-yield Nasdaq-100 income vehicle. The fund uses a laddered ...
Retail traders drove a large share of leveraged ETF activity in late 2025 as markets swung. This piece examines the p...
As drone-saturated battlefields rise, the world’s most advanced tanks drive a new era of defense spending. This repor...
A notable fund liquidated its entire Ascendis Pharma stake, signaling a strategic rotation in a volatile biotech sect...
In 2022, the S&P 500 plunged while a healthcare-focused ETF held its ground better than most. This story examines why...
Stocks rally on the back of a surge in corporate profits, with BEA data showing Q4 2025 profits at $4.35 trillion. Th...
Bitcoin dips below $72,000 as several altcoins surge with double-digit gains, creating a mixed market mood and renewe...
A leveraged move hit the market hard as ETHT tumbled while ETH breached the $1,600 mark, highlighting the dangers of ...
Micron shares slide 6% and Western Digital declines 5% in midday trading, even as SanDisk steadies. The move comes as...
The AI boom is reshaping the tech stock landscape, putting Nvidia and Micron in the spotlight. This guide teases out ...